Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy without an available effective systemic chemotherapy. Insulin growth factor 2 (IGF-2) overexpression leading to the activation of the IGF-1 receptor (IGF-1R)/mammalian target of rapamycin (mTOR) pathway is well...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Naing, A, LoRusso, P, Fu, S, Hong, D, Chen, H X, Doyle, L A, Phan, A T, Habra, M A, Kurzrock, R
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2013
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3590681/
https://ncbi.nlm.nih.gov/pubmed/23412108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.46
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki